ClinicalTrials.gg
Not yet recruitingNCT07312149BoxTerUpdated Nov 19, 2026

Isolation of Pulmonary Veins Using the Box Technique in Patients Undergoing Sternotomy

An observational study in Atrial Fibrillation (AF) and Cardiac Surgery, sponsored by Nantes University Hospital. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Nantes University Hospital · Observational

How we know

Updated Nov 19, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 317 studies in Atrial Fibrillation with a site in France — 63 open to participants now, 87 under way, 5 of them phase 3. Atrial Fibrillation · France.

Planned enrollment
71st of 123
200 · median 250
Started
2026
with 14 others
Observational
124 of 317
25 open now
Primary completion
2030-12
later than 83 of 86 live
Registered
301st of 317
by date
Lead sponsor
8 of 317
Nantes University Hospital

Among the 317 studies in Atrial Fibrillation with a site in France, this one is the 71st largest by planned enrollment of the 123 observational ones that give a count, is one of 15 that started in 2026, is one of 124 observational ones, reaches primary completion later than 83 of the 86 other live ones, and was the 301st registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

63 of the 317 studies in Atrial Fibrillation with a site in France are open now. Recruiting first, the newest first:

58 more — sign in →

All 63 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 317 studies in Atrial Fibrillation with a site in France, or all of them as a file.
02

Study summary

Atrial Fibrillation (AF) is the most common cardiac arrhythmia worldwide, affecting approximately 2.8% of the population, with prevalence increasing with age. AF is associated with significant morbidity and mortality, accounting for about 25% of ischemic strokes, 10% of cryptogenic strokes, and a 10-40% annual increase in hospital admissions due to heart failure or anticoagulant-related events.

About 10% of patients undergoing cardiac surgery have preoperative AF. In 1986, Dr. Cox introduced the MAZE procedure, a surgical technique to isolate AF triggers. Initially involving atrial incisions, it evolved to use radiofrequency lines, significantly reducing morbidity and mortality. The MAZE procedure is now strongly recommended (Class Ia evidence) for concomitant cardiac surgery. However, nearly 85% of eligible patients-especially those undergoing closed-chest cardiac surgery-do not receive this treatment due to technical challenges and limited reproducibility of the Cox-Maze IV technique.

Pulmonary Vein Isolation (PVI) with posterior wall isolation (PWI-Box) has emerged as an effective alternative, offering similar outcomes to Cox-Maze IV with fewer adverse effects. Innovative devices like the GeminiS (Medtronic) enable minimally invasive, thoracoscopic PVI-PWI-Box procedures without opening the heart, even off-pump. This approach could expand the use of AF ablation during combined sternotomy surgeries, aligning with clinical guidelines.

Primary Objective: Assess the efficacy of PWI-Box using GeminiS combined with other cardiac surgeries via sternotomy.

Primary Endpoint: Recurrence rate of paroxysmal or persistent AF (per ESC definition) at 1 year postoperatively, confirmed by 24-hour Holter monitoring.

03

Conditions studied

  • Atrial Fibrillation (AF)
  • Cardiac Surgery

Browse trials for

Keywords

  • Atrial firbrillation
  • Cardiac Surgery
  • PWI-Box
  • GeminiS
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with a surgical indication for AF in combination with conventional cardiac surgery performed by sternotomy (coronary artery bypass grafting, aortic valve replacement, aortic surgery, etc.). Patients may be included prospectively, via information provided by the attending physician during a consultation (written and oral), or retrospectively for those who have already undergone surgery, by sending an information notice with a non-objection period.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients undergoing cardiac surgery via sternotomy
  • Concomitant use of the PWI box with GeminiS during surgery
  • Adult patients
  • Patients with the following characteristics: Preoperative paroxysmal/persistent/permanent AF; Duration of less than 5 years; And left atrium volume \<60 ml/m2
  • Informed patient who did not object to the collection of their data for the study

Exclusion criteria

Exclusion criteria:

  • Unplanned surgery (emergency)
  • History of cardiac surgery (reoperation)
  • Pregnant or breastfeeding women
  • Adults under guardianship, curatorship or judicial protection
  • Patients with a of less than three years
  • Patients currently taking medication or using an experimental device that clinically interferes with the study's evaluation criteria and results.
  • Inability to comply with the monitoring schedule.
  • to long-term anticoagulants
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • BOXTER Study population

    Patients with a surgical indication for AF in combination with conventional cardiac surgery performed by sternotomy (coronary artery bypass grafting, aortic valve replacement, aortic surgery, etc.).

    Other: Collection of study data from patient records

Interventions

  • OtherCollection of study data from patient records

    Collection of study data from patient records in the EPICARD national database at the time of surgery, 1 month post-surgery, 12 months post-surgery, 24 months post-surgery and 36 months post-surgery.

06

What researchers measure

Primary outcomes

  1. Evaluate the efficacy of the PWI box, using GeminiS in combination with other cardiac surgery procedures via sternotomy, at 1 year post-operatively using 24-hour Holter monitoring.

    Time frame: 12 months

Secondary outcomes

  1. Evaluation of the efficacy of the PWI box using GeminiS in combination with other cardiac surgery procedures via sternotomy at 2 years postoperatively.

    Time frame: 24 months

  2. Evaluation of the efficacy of the PWI box using GeminiS in combination with other cardiac surgery procedures via sternotomy at 3 years postoperatively.

    Time frame: 36 months

  3. Evaluation of the rate of secondary endocardial ablation of AF.

    Time frame: 12 months

  4. Evaluation of clinicals predictive factors for recurrence of AF after MAZE.

    Time frame: 36 months

  5. Evaluate the rate of patients on anticoagulant and/or antiarrhythmic therapy after MAZE surgery.

    Time frame: 36 months

  6. Assessment of complication rates associated with the technique used during cardiac surgery.

    Time frame: 36 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Dec 2026; primary completion for Dec 2030, 48 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: start Oct 2026 → Dec 2026, primary completion Oct 2030 → Dec 2030 and completion Oct 2032 → Dec 2032.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2025
First posted
Dec 31, 2025
StartEst.
Dec 5, 2026was Oct 2026
Primary completionEst.
Dec 5, 2030was Oct 2030
CompletionEst.
Dec 5, 2032was Oct 2032
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 5, 2026→Dec 5, 2026
Nov 19, 2026
Primary completion
Oct 5, 2030→Dec 5, 2030
Nov 19, 2026
Study completion
Oct 5, 2032→Dec 5, 2032
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Start date Oct 5, 2026→Dec 5, 2026
    Primary completion Oct 5, 2030→Dec 5, 2030
    Study completion Oct 5, 2032→Dec 5, 2032
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07312149
Responsible party
Sponsor
First posted
Dec 31, 2025
Start date
Dec 5, 2026 (estimated)
Primary completion
Dec 5, 2030 (estimated)
Completion
Dec 5, 2032 (estimated)
Last update
Nov 19, 2026

Study contacts

Sponsor
Contact
bp-prom-regl@chu-nantes.fr
02 53 48 28 35 ext. +33
Charles-Henri DAVID
study director · Nantes University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion